CY1125075T1 - Εκχυλισμα salvia haenkei σαν δραστικος παραγοντας στις διαδικασιες επανεπιθηλιωσης και επουλωσης ιστων - Google Patents

Εκχυλισμα salvia haenkei σαν δραστικος παραγοντας στις διαδικασιες επανεπιθηλιωσης και επουλωσης ιστων

Info

Publication number
CY1125075T1
CY1125075T1 CY20221100211T CY221100211T CY1125075T1 CY 1125075 T1 CY1125075 T1 CY 1125075T1 CY 20221100211 T CY20221100211 T CY 20221100211T CY 221100211 T CY221100211 T CY 221100211T CY 1125075 T1 CY1125075 T1 CY 1125075T1
Authority
CY
Cyprus
Prior art keywords
tissue
resipheralization
active agent
healing processes
salvia haenkei
Prior art date
Application number
CY20221100211T
Other languages
English (en)
Inventor
Andrea Alimonti
Andrea Maria GIORI
Monica MONTOPOLI
Jessica CADAU
Original Assignee
Altergon S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altergon S.A. filed Critical Altergon S.A.
Publication of CY1125075T1 publication Critical patent/CY1125075T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/537—Salvia (sage)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/722—Chitin, chitosan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/38—Silver; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/02—Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Cosmetics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Περιγράφεται η χρήση του εκχυλίσματος Salvia haenkei σαν παράγοντα επανεπιθηλιοποίησης και επούλωσης στη θεραπεία βλαβών ιστών. Επίσης κοινοποιούνται φαρμακευτικές συνθέσεις που περιλαμβάνουν εκχύλισμα Salvia haenkei και κατάλληλα φαρμακευτικά αποδεκτά έκδοχα για χρήση στη θεραπεία βλαβών ιστών.
CY20221100211T 2017-12-19 2022-03-16 Εκχυλισμα salvia haenkei σαν δραστικος παραγοντας στις διαδικασιες επανεπιθηλιωσης και επουλωσης ιστων CY1125075T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT201700146620 2017-12-19
PCT/EP2018/085067 WO2019121425A1 (en) 2017-12-19 2018-12-14 Use of a vegetal extract as an active agent in tissue re-epithelizing and cicatrizing processes

Publications (1)

Publication Number Publication Date
CY1125075T1 true CY1125075T1 (el) 2023-06-09

Family

ID=61802257

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20221100211T CY1125075T1 (el) 2017-12-19 2022-03-16 Εκχυλισμα salvia haenkei σαν δραστικος παραγοντας στις διαδικασιες επανεπιθηλιωσης και επουλωσης ιστων

Country Status (11)

Country Link
US (1) US11235016B2 (el)
EP (1) EP3727414B1 (el)
CN (1) CN111565735A (el)
CA (1) CA3084280A1 (el)
CY (1) CY1125075T1 (el)
DK (1) DK3727414T3 (el)
ES (1) ES2909243T3 (el)
MA (1) MA51277A (el)
PL (1) PL3727414T3 (el)
PT (1) PT3727414T (el)
WO (1) WO2019121425A1 (el)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT202100017678A1 (it) * 2021-07-05 2023-01-05 Altergon Sa Use of a vegetal extract as an active agent in the treatment of a musculoskeletal disorder / uso di un estratto vegetale come agente attivo nel trattamento di patologia muscolo-scheletrica
IT202100017666A1 (it) * 2021-07-05 2023-01-05 Altergon Sa Use of a vegetal extract as an active agent in the treatment of heart diseases / uso di un estratto vegetale come agente attivo nel trattamento di patologie cardiache
CN114480543A (zh) * 2022-01-29 2022-05-13 淮安唯尔美化妆品有限公司 一种植物酶解肽及其抑制瘢痕、制备抑制瘢痕化妆品的用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3969516A (en) * 1974-12-19 1976-07-13 Nelson Research & Development Company Composition and method for treatment of acne
DE4303823C2 (de) * 1993-02-10 1997-08-07 Isernhagen Heilmittelbetr Gmbh Verwendung eines Extraktes aus Blüten von Salvia officinalis bei der Bekämpfung von Durchblutungsstörungen
CN103845232A (zh) * 2012-12-06 2014-06-11 叶海涛 除皱护理复方浴盐
ITRM20130063A1 (it) * 2013-01-31 2014-08-01 Atrahasis S R L Metodo di screening per identificare sostanze per contrastare l'invecchiamento.

Also Published As

Publication number Publication date
RU2020118154A (ru) 2022-01-20
ES2909243T3 (es) 2022-05-06
CA3084280A1 (en) 2019-06-27
US20200376064A1 (en) 2020-12-03
CN111565735A (zh) 2020-08-21
DK3727414T3 (da) 2022-03-28
MA51277A (fr) 2021-03-31
PT3727414T (pt) 2022-03-25
EP3727414B1 (en) 2022-01-26
US11235016B2 (en) 2022-02-01
PL3727414T3 (pl) 2022-05-09
EP3727414A1 (en) 2020-10-28
RU2020118154A3 (el) 2022-04-14
WO2019121425A1 (en) 2019-06-27

Similar Documents

Publication Publication Date Title
CY1125075T1 (el) Εκχυλισμα salvia haenkei σαν δραστικος παραγοντας στις διαδικασιες επανεπιθηλιωσης και επουλωσης ιστων
CY1116511T1 (el) Μεθοδος αγωγης του κολπικου ινιδισμου
MX2021004639A (es) Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para uso en el tratamiento de tumores solidos.
MX2021004110A (es) Composiciones farmaceuticas que comprenden n-(3,5- dimetoxifenil)-n'-(1-metiletil)-n-[3-(1-metil-1h- pirazol-4-il)quinoxalin-6-il]etano-1,2-diamina.
MX2021004546A (es) Composiciones de suministro de farmaco implantables y metodos de uso de las mismas.
BR112020015688A8 (pt) Formulações tópicas que compreendem tofacitinibe
MX2020008258A (es) Formulaciones pediátricas de niraparib y métodos de tratamiento pediátricos.
BR112016000335A8 (pt) método de tratamento da rosácea papulopustular, de tratamento de lesões inflamatórias da rosácea papulopustular e uso de uma composição farmacêutica
BR112017016087A2 (pt) formulações para coxim articular adiposo e métodos de uso das mesmas
DOP2016000254A (es) Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso.
MX2021009051A (es) Tratamiento de lesiones cutaneas y prurito en pacientes con prurigo nodular.
BR112017009510A2 (pt) composições compreendendo ciclosporina
CO2023013050A2 (es) Composiciones de psilocibina, métodos para prepararlas y métodos de uso de estas
CY1119532T1 (el) (s)-πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη
MX2022014792A (es) Cocristales, composiciones farmaceuticas de los mismos y metodos de tratamiento que los implican.
CR20160495A (es) Composiciones libres de células para la restauración de células y métodos para la preparación y utilización de las mismas
WO2019151964A3 (en) Orally disintegrating formulations of saxagliptin
MX2019011951A (es) Secretoma bacteriano para usarse en el tratamiento contra lesiones cutaneas.
BR112019017314A2 (pt) composições farmacêuticas para terapia de combinação
MX2019008847A (es) Profarmacos de cisteamina.
MX2018008196A (es) Tratamiento para cancer de mama usando una combinacion de una formulacion liposomal cationica de taxano, una formulacion no liposomal de taxano y un agente activo adicional.
TR201619953A2 (tr) Topi̇kal terapöti̇k formülasyonlar
CO2024002715A2 (es) Formulaciones de radiprodil
CO2018008201A1 (es) Formulación en crema a base de glicirricina para el tratamiento tópico de la leishmaniasis cutánea.
AR101227A1 (es) Combinaciones de un derivado de n-tiazolil-4-fenoxibencenosulfonamida y un agente farmacéuticamente activo seleccionado a partir de gabapentina y pregabalina para tratar dolor